Nothing Special   »   [go: up one dir, main page]

BR112017016465A2 - heterocyclic compound and pharmaceutical composition comprising it - Google Patents

heterocyclic compound and pharmaceutical composition comprising it

Info

Publication number
BR112017016465A2
BR112017016465A2 BR112017016465-5A BR112017016465A BR112017016465A2 BR 112017016465 A2 BR112017016465 A2 BR 112017016465A2 BR 112017016465 A BR112017016465 A BR 112017016465A BR 112017016465 A2 BR112017016465 A2 BR 112017016465A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
heterocyclic compound
heterocyclic
compound
pharmaceutical
Prior art date
Application number
BR112017016465-5A
Other languages
Korean (ko)
Portuguese (pt)
Other versions
BR112017016465B1 (en
Inventor
Min Changhee
Oh Byungkyu
Kim Yongeun
Park Changmin
Original Assignee
Beyondbio Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beyondbio Inc. filed Critical Beyondbio Inc.
Publication of BR112017016465A2 publication Critical patent/BR112017016465A2/en
Publication of BR112017016465B1 publication Critical patent/BR112017016465B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112017016465-5A 2015-02-04 2016-02-02 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING IT BR112017016465B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2015-0017339 2015-02-04
KR20150017339 2015-02-04
PCT/KR2016/001133 WO2016126085A2 (en) 2015-02-04 2016-02-02 Heterocyclic compound and pharmaceutical composition comprising same

Publications (2)

Publication Number Publication Date
BR112017016465A2 true BR112017016465A2 (en) 2018-06-19
BR112017016465B1 BR112017016465B1 (en) 2023-11-14

Family

ID=56564854

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017016465-5A BR112017016465B1 (en) 2015-02-04 2016-02-02 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING IT

Country Status (14)

Country Link
US (3) US10227328B2 (en)
EP (1) EP3255042B1 (en)
JP (1) JP6615899B2 (en)
KR (1) KR101783642B1 (en)
CN (1) CN107250130B (en)
AU (1) AU2016216253B2 (en)
BR (1) BR112017016465B1 (en)
CA (1) CA2974788C (en)
DK (1) DK3255042T3 (en)
ES (1) ES2854707T3 (en)
IL (1) IL253538B (en)
RU (1) RU2710743C2 (en)
SG (1) SG11201705952SA (en)
WO (1) WO2016126085A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102444835B1 (en) 2016-05-26 2022-09-19 리커리엄 아이피 홀딩스, 엘엘씨 EGFR inhibitor compounds
WO2020047518A1 (en) * 2018-08-30 2020-03-05 The Regents Of The University Of California Ire1 kinase inhibitors and uses thereof
CA3127958A1 (en) * 2019-01-29 2020-08-06 Beta Pharma, Inc. 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases
KR102443873B1 (en) * 2019-09-06 2022-09-19 비욘드바이오주식회사 Process for Preparing Pyrimidinyl Bipyridine Compound and Intermediate Therefor
KR20210029693A (en) 2019-09-06 2021-03-16 비욘드바이오주식회사 2,6-Bis-(2-aminopyrimidin-4-yl)pyridin-3-ol dihydrochloride and pharmaceutical composition comprising the same
WO2021045586A1 (en) * 2019-09-06 2021-03-11 비욘드바이오주식회사 2'-amino-6-(2-amino-6-(1-isopropylpiperidin-4-yl)-5-methylpyrimidin-4-yl)-3'-fluoro-[2,4'-bipyridine]-5-ol 3-hydrochloride and pharmaceutical composition comprising same
KR20210029694A (en) 2019-09-06 2021-03-16 비욘드바이오주식회사 2'-Amino-6-(2-amino-6-methylpyrimidin-4-yl)-3'-fluoro-[2,4'-bipyridin]-5-ol dihydrochloride and pharmaceutical composition comprising the same
US20230019999A1 (en) * 2019-11-18 2023-01-19 Chugai Seiyaku Kabushiki Kaisha Combination drug
CN111558044B (en) * 2020-06-01 2022-02-11 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) Pharmaceutical composition containing sunitinib, and preparation and application thereof
CN116082310B (en) * 2023-02-17 2024-08-20 厦门大学 Bipyridine amide derivative, and preparation and application thereof
CN116751195A (en) * 2023-06-21 2023-09-15 杭州科兴生物化工有限公司 Bipyridine compound, pharmaceutically acceptable salt thereof, preparation method and application

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
GB0013655D0 (en) * 2000-06-05 2000-07-26 Prolifix Ltd Therapeutic compounds
US6949571B2 (en) * 2000-06-12 2005-09-27 Eisai Co., Ltd. 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
JP2004534779A (en) * 2001-05-30 2004-11-18 エルジー ライフサイエンス リミテッド Protein kinase inhibitors for disease treatment
GB0129260D0 (en) * 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
WO2004016597A2 (en) * 2002-08-14 2004-02-26 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
CN1742723A (en) 2004-09-02 2006-03-08 天津倍方科技发展有限公司 Medicine composition containing temozolomide-8-carboxylic ether and use of such compound for preparing anti-tumor medicine
WO2008106202A1 (en) * 2007-02-27 2008-09-04 Housey Gerard M Theramutein modulators
WO2010018458A2 (en) * 2008-08-12 2010-02-18 Crystalgenomics, Inc. Phenol derivatives and methods of use thereof

Also Published As

Publication number Publication date
NZ734084A (en) 2023-09-29
US10227328B2 (en) 2019-03-12
SG11201705952SA (en) 2017-09-28
CN107250130A (en) 2017-10-13
EP3255042A4 (en) 2018-08-01
DK3255042T3 (en) 2021-02-08
CN107250130B (en) 2019-11-08
AU2016216253B2 (en) 2019-11-21
RU2017130825A (en) 2019-03-04
US10611754B2 (en) 2020-04-07
AU2016216253A1 (en) 2017-08-17
RU2710743C2 (en) 2020-01-10
ES2854707T3 (en) 2021-09-22
CA2974788C (en) 2023-04-11
US20200190062A1 (en) 2020-06-18
IL253538A0 (en) 2017-09-28
JP6615899B2 (en) 2019-12-04
BR112017016465B1 (en) 2023-11-14
KR101783642B1 (en) 2017-10-10
JP2018504449A (en) 2018-02-15
KR20160096033A (en) 2016-08-12
US20180273510A1 (en) 2018-09-27
WO2016126085A3 (en) 2016-11-03
EP3255042B1 (en) 2020-12-30
EP3255042A2 (en) 2017-12-13
RU2017130825A3 (en) 2019-08-12
IL253538B (en) 2020-09-30
WO2016126085A2 (en) 2016-08-11
CA2974788A1 (en) 2016-08-11
US20190135786A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
DK3256138T3 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING MELOXICAM
DK3529248T3 (en) Pharmaceutical compositions
DK3495023T3 (en) SEMIFLUOROIATED COMPOUNDS AND COMPOSITIONS THEREOF
BR112017016465A2 (en) heterocyclic compound and pharmaceutical composition comprising it
DK3357513T3 (en) PHARMACEUTICAL COMPOSITION AND USE THEREOF
BR112016015706A2 (en) compound, use of it and pharmaceutical composition
DK3416996T3 (en) HARDLY COMPOSITION
ES2796177T5 (en) Pharmaceutical composition
DK3102200T3 (en) Therapeutic compound and composition
DK3529240T3 (en) Pharmaceutical compounds
DK3532029T3 (en) Liquid pharmaceutical composition
DK3554534T3 (en) PHARMACEUTICAL COMPOSITION INCLUDING INSULIN
DK3528902T3 (en) RINGEGEL COMPOSITION
DK3275452T3 (en) PHARMACEUTICAL COMPOSITION WITH SILIBININE
DK3583943T3 (en) PHARMACEUTICAL COMPOSITION
DK3672948T3 (en) PYRIDINAMINE-PYRIDONE AND PYRIMIDINAMINE-PYRIDONE COMPOUNDS
PT3202759T (en) Alpha-aminoamide derivative compound and pharmaceutical composition comprising same
DK3388085T3 (en) PHARMACEUTICAL COMPOSITION AND USES THEREOF
DK3328368T3 (en) Compounds and pharmaceutical composition associated with ubiquitination-proteasome system
DK3393254T3 (en) COMPOSITION
DK3302483T3 (en) PHARMACEUTICAL COMPOSITIONS AND APPLICATION THEREOF
DK3416502T3 (en) GLYCEMIC-REDUCING COMPOSITION
DK3288933T3 (en) OXINDOL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF
DK3357520T3 (en) VISCOELASTIC COMPOSITION
DK3322295T3 (en) COMPOSITION

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/02/2016, OBSERVADAS AS CONDICOES LEGAIS